Asston Pharmaceuticals IPO Review

Asston Pharmaceuticals is engaged in the manufacturing and export of both pharmaceutical formulations and nutraceutical products in domestic and various African markets. Their Company operates under brand “Asston”. Presently, the Company is involved in the business of manufacturing and marketing of Tablets, Capsules, Oral Liquid, External Preparations (Ointment, Cream, Gel and Lotion) and Oral Powder (Sachet, Dry Syrup) etc.

The Company has experienced significant growth, with a current strength of over 50 team members and growing. The team operates under the leadership of the promoters, Dr. Ashish Sakalkar, Mrs. Saili More and Mr. Sachin Badakh, who possesses an expertise in formulations, market operations, and exports of healthcare product in the pharmaceutical industry.

The Revenues from operations for the Period ended on May 31, 2025 and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 620.93, ₹ 2,561.02 Lakh, ₹ 1,584.09 Lakh and ₹ 719.19 Lakh. The EBITDA for the Period ended on May 31, 2025 and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 194.90, ₹ 673.03 Lakh, ₹ 280.06 Lakh and ₹ 217.05 Lakh. The Profit after Tax for the Period ended on May 31, 2025 and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹ 132.24, ₹ 432.51 Lakh, ₹ 136.03 Lakh and ₹ 105.66 Lakh respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue EPS of ₹ 6.9 and post-issue EPS of ₹ 5.08 for FY24. The pre-issue P/E ratio is 17.83x, while the post-issue P/E ratio is 24.21x. The company's ROCE for FY24 is 51.25%, ROE for FY24 is 50.56% and RoNW is 40.36%. The Annualised EPS is ₹ 9.32 and the Annualised P/E Ratios is 13.20x. These metrics suggest that the IPO is fully priced.

The Grey Market Premium (GMP) of Asston Pharmaceuticals showing listing gains of 17.88 %.Given the company's financial performance and the valuation of the IPO, we recommend Risky Investors to Apply to the Asston Pharmaceuticals Limited IPO for Listing gain.

Disclaimer: The information provided in this IPO review is for educational and informational purposes only and should not be construed as financial advice or an offer to buy or sell securities. The review must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. The content is based on publicly available information and market perceptions as of the date of publication and is subject to change. Neither the author nor the website is responsible for any losses or damages arising from the use of this information. 1.“Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.” 2. “Investment in securities market are subject to market risks. Read all the related documents carefully before investing.” 3. To read the Disclaimers, Disclosures, Investor Charter, Investor Complaints please visit our website abhayvarn.com

About the Author
CA Abhay Kumar (Also known as  CA Abhay Varn) is a qualified Chartered Accountant by profession and cleared CA at age 21. He is a SEBI Registered Research Analyst with Registration Number - INH300008465. He Possesses 8+ years of experience in the Stock Market Field and has also worked in Big CA firms.